Ozempic, Mounjaro weight reduction drug makers sued by Louisiana girl
A Louisiana girl is suing the makers of the injectable drugs Ozempic and Mounjaro after she mentioned she suffered extreme gastrointestinal points after taking the medication.
The drug semaglutide, which is used for the model Ozempic and Wegovy, was developed to deal with diabetes however has grow to be a preferred approach to assist individuals drop a few pounds, with a number of celebrities admitting to taking it.
Within the lawsuit filed Aug. 2, attorneys for Jaclyn Bjorklund mentioned she used Ozempic for over a yr till beginning earlier than taking Mounjaro in July 2023. The 44-year-old girl is suing the makers for each medication Novo Nordisk and Eli Lilly for failing to warn of the chance of gastroparesis and gastroenteritis.
“Because of utilizing Defendants’ Ozempic and Mounjaro, Plaintiff was induced to undergo from extreme gastrointestinal occasions, and because of this sustained extreme and everlasting private accidents, ache, struggling, and emotional misery, and incurred medical bills,” the lawsuit reads.
Ozempic, Wegovy, Mounjaro:How these drugs promote weight reduction – and what you have to know
Affected person was hospitalized with abdomen ache, go well with says
Bjorklund skilled extreme vomiting, gastrointestinal burning and was hospitalized for abdomen ache, the go well with alleges. A few of her enamel fell out in the course of the extreme vomiting, and she or he threw up entire meals hours after consuming, the doc added.
The go well with mentioned the drug makers did not disclose the hyperlink between GLP-1 agonists and the chance of creating extreme gastrointestinal points, making the remedy warnings inadequate — the doc, nevertheless not say whether or not Bjorklund was identified with gastroparesis.
USA TODAY has reached out to Bjorklund’s attorneys for remark.
The lawsuit seeks compensatory and punitive damages for all of the ache, struggling, emotional misery and incurred medical bills that Bjorklund endured, legal professional’s charges and extra courtroom prices confronted in the course of the litigation course of.
Each drug makers checklist unintended effects on medication
Not like Novo Nordisk’s Ozempic and and Wegovy, which use semaglutide, Eli Lilly makes use of tripeptide for Mounjaro. Each semaglutide and tripeptide mimic a the naturally made hormone GLP-1 to sluggish the passage of meals to the abdomen to sluggish the method of turning into hungry.
The prescribing info for Ozempic states taking the drug comes with the chance of frequent opposed occasions reminiscent of nausea, vomiting, diarrhea, stomach ache, and constipation. Within the part detailing drug interactions, Novo Nordisk notes that Ozempic can presumably sluggish gastric emptying, which may have an effect on the absorption of oral drugs.
Uncomfortable side effects and longterm results:Why consultants fear the ‘magic’ in new weight reduction drugs carries a darkish facet
Equally, Mounjaro’s prescribing info lists predominant opposed occasions together with nausea, diarrhea, decreased urge for food, vomiting, constipation, dyspepsia and stomach ache. Eli Lilly highlights that Mounjaro can presumably delay gastric emptying, probably resulting in impacts on the absorption of medicines.
“Affected person security is of utmost significance to Novo Nordisk,” a spokesperson for Novo Nordisk instructed USA TODAY in response to the lawsuit. “We’re repeatedly monitoring the security profile of our merchandise and collaborate carefully with authorities to make sure affected person security, together with ample info on gastrointestinal unintended effects within the label.”
Novo Nordisk added gastrointestinal occasions are “well-known unintended effects of the GLP-1 class” and in the case of semaglutide, most GI unintended effects are gentle to average in severity and quick lasting.
“Affected person security is Lilly’s prime precedence, and we actively interact in monitoring, evaluating and reporting security info for all our medicines,” an Eli Lilly consultant instructed USA TODAY.
